ERBB2 and cancer: Treatment of RTK-driven cancer cell lines with zotatifin for 24 h resulted in dose dependent downregulation of HER2, FGFR1 and FGFR2 protein levels, as well as cyclin D1 (a zotatifin target gene (6), Figure 1C, Supplementary Figure S1A).